Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Toll Brothers Announces Model Homes Opening at Alora in Orlando, Florida

April 24, 2026

Ribonucleic Acid (RNA) Therapy Clinical Trials Research Report 2026: $3.4 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 24, 2026

Town of Peace River, Alta. cancels evacuation alert as flood threat recedes

April 24, 2026

Pediatric Clinical Trials Research Report 2026: $26.67 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 24, 2026

AI-Based Clinical Trial Solution Providers Research Report 2026: $8.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 24, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Teradata
Press Release

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Teradata

By News RoomAugust 8, 20245 Mins Read
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Teradata
Share
Facebook Twitter LinkedIn Pinterest Email

If you suffered losses exceeding $100,000 investing in Teradata stock or options between February 13, 2023 and February 12, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/TDC.

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Teradata Corporation (“Teradata” or the “Company”) (NYSE: TDC) and reminds investors of the August 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) under Teradata’s expanded business model, which involved engagement with additional customer business units and decisionmakers, transactions with the Company’s customers took longer to finalize; (ii) Teradata thus overstated its ability to close customer transactions within their intended timeframes under its expanded business model; (iii) Teradata failed to timely close several customer transactions that it had factored into its outlook for 2023 ARR growth; (iv) as a result, the Company was unlikely to meet its full year 2023 Total and Public Cloud ARR expectations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On December 7, 2023, at a Barclays Global Technology Conference Teradata’s Chief Financial Officer Defendant Claire Bramley revealed that the Company had “an eight-figure deal that potentially [. . .] could get pushed out [of Q4 2023]”, the effect of which “could put [the Company] towards the low end or slightly below the range for cloud ARR that [it] previously gave.”

On this news, Teradata’s stock price fell $2.89 per share, or 6.24%, to close at $43.40 per share on December 7, 2023.

Then, on February 12, 2024, Teradata announced its Q4 and full year 2023 financial results. Among other things, the Company stated that due to “deal timing issues” public cloud ARR increased by only 48% and total ARR increased by only 6% for the full year 2023, falling well short of the Company’s previously issued expectations for these performance metrics.

On a conference call held that same day to discuss the Company’s Q4 and full year 2023 results (the “Q4 2023 Earnings Call”), Teradata’s Chief Executive Officer Defendant Stephen McMillan (“McMillan”) confirmed that the “deal timing issues” related to the Company’s failure to timely finalize certain transactions that would have contributed to full year ARR growth if they had been closed in 2023. Specifically, Defendant McMillan claimed that because “Teradata is becoming even more strategic to corporations and touching all levels of [its] customers’ organizations,” there were “more executive decision makers” required to close these deals and that “[t]hese dynamics cause a number of transactions to move into 2024.” As a result, Defendant McMillan revealed that “there was a handful of large deals that slipped out of December [2023] and each were worth $2 million or more of cloud ARR growth.”

On this news, Teradata’s stock price fell $10.57 per share, or 21.66%, to close at $38.22 per share on February 13, 2024.

As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the Company’s securities, Plaintiff and other Class members have suffered significant losses and damages.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Teradata’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Teradata class action, go to www.faruqilaw.com/TDC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e848124-9c14-4bab-ba13-256ecec0c433

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Toll Brothers Announces Model Homes Opening at Alora in Orlando, Florida

Ribonucleic Acid (RNA) Therapy Clinical Trials Research Report 2026: $3.4 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Pediatric Clinical Trials Research Report 2026: $26.67 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

AI-Based Clinical Trial Solution Providers Research Report 2026: $8.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Clinical Trial Software Research Report 2026: $2.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

BitsStrategy Offers Free AI Stock Trading Bot to Help Users Unlock New Quantitative Trading Opportunities

Top Technology Executives Recognized at the 2026 HoustonCIO ORBIE Awards 

Mental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

The European market demands vehicles like this! iCAUR Unveils New Concept Car at Beijing Auto Show

Editors Picks

Ribonucleic Acid (RNA) Therapy Clinical Trials Research Report 2026: $3.4 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 24, 2026

Town of Peace River, Alta. cancels evacuation alert as flood threat recedes

April 24, 2026

Pediatric Clinical Trials Research Report 2026: $26.67 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 24, 2026

AI-Based Clinical Trial Solution Providers Research Report 2026: $8.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 24, 2026

Latest News

Clinical Trial Software Research Report 2026: $2.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 24, 2026

BMW is one step closer to selling you a color-changing car

April 24, 2026

BitsStrategy Offers Free AI Stock Trading Bot to Help Users Unlock New Quantitative Trading Opportunities

April 24, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version